Exemestane - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for exemestane and what is the scope of patent protection?
Exemestane
is the generic ingredient in two branded drugs marketed by Pfizer, Alvogen, Amneal Pharms, Breckenridge, Cipla, Dr Reddys Labs Sa, Eugia Pharma, Hikma, Qilu, Rising, Upsher Smith Labs, and Zydus Pharms, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.There are fifteen drug master file entries for exemestane. Thirteen suppliers are listed for this compound.
Summary for exemestane
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 12 |
NDAs: | 12 |
Drug Master File Entries: | 15 |
Finished Product Suppliers / Packagers: | 13 |
Raw Ingredient (Bulk) Api Vendors: | 100 |
Clinical Trials: | 254 |
Patent Applications: | 5,922 |
Drug Prices: | Drug price trends for exemestane |
What excipients (inactive ingredients) are in exemestane? | exemestane excipients list |
DailyMed Link: | exemestane at DailyMed |
Recent Clinical Trials for exemestane
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Breast Cancer Research Foundation | Phase 2 |
QuantumLeap Healthcare Collaborative | Phase 2 |
NRG Oncology | Phase 2 |
Pharmacology for exemestane
Drug Class | Aromatase Inhibitor |
Mechanism of Action | Aromatase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for exemestane
US Patents and Regulatory Information for exemestane
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Qilu | EXEMESTANE | exemestane | TABLET;ORAL | 213547-001 | Apr 13, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Upsher Smith Labs | EXEMESTANE | exemestane | TABLET;ORAL | 209208-001 | Jul 26, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Hikma | EXEMESTANE | exemestane | TABLET;ORAL | 077431-001 | Apr 1, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Alvogen | EXEMESTANE | exemestane | TABLET;ORAL | 200898-001 | Jul 28, 2014 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for exemestane
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer | AROMASIN | exemestane | TABLET;ORAL | 020753-001 | Oct 21, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Pfizer | AROMASIN | exemestane | TABLET;ORAL | 020753-001 | Oct 21, 1999 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.